ct-p59
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jul 18, 2020 (NCT04525079)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, passive
SARS-CoV-2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04602000 | Phase 2/Phase 3 (Phase 3) | Sep 25, 2020 | Celltrion |
| NCT04593641 | Phase 1 | Sep 4, 2020 | Celltrion |
| NCT04525079 | Phase 1 | Jul 18, 2020 | Celltrion |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celltrion | For profit | 3 | 3 | 2 | 2020 |
1 organizations
Page 1 / 1